Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer
- 10 July 2008
- journal article
- breast cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (20) , 3317-3323
- https://doi.org/10.1200/jco.2007.13.5202
Abstract
Purpose The combination of lapatinib and trastuzumab has been observed to have a synergistic, antiproliferative effect against ErbB2-positive breast cancer cells in vitro. This phase I study assess...Keywords
This publication has 19 references indexed in Scilit:
- Lapatinib: Current Status and Future Directions in Breast CancerThe Oncologist, 2006
- Long-Term Follow-Up After Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia/Myelodysplastic Syndrome: Late CNS Relapses Despite Graft-Versus-Host DiseaseJournal of Clinical Oncology, 2006
- Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer CellsCancer Research, 2006
- p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast CancerClinical Cancer Research, 2006
- Expression profiling of androgen-dependent and -independent LNCaP cells: EGF versus androgen signallingEndocrine-Related Cancer, 2005
- A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)Cancer Research, 2004
- Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016Oncogene, 2004
- Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathwaysOncogene, 2002
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987